

The National Pancreatic Cancer Audit (NPaCA) evaluates patterns of care and outcomes for people with a diagnosis of pancreatic cancer across England and Wales. It aims to support NHS pancreatic cancer services to identify and address areas for improvement.

Key to the audit's impact has been its ability to add value across national initiatives, through successful collaboration with partners including Pancreatic Cancer UK (PCUK), the GIRFT Pancreatic cancer project team and NHSE's Treatment Variation Working Group.



NPaCA data have been used by Pancreatic Cancer UK to support discussions with both Members of Parliament and Members of the Senedd. This has enabled the charity to make the case for national and constituency level improvements.



NHS England's Treatment Variation Working Group (TVWG) have used NPaCA generated data and performance indicators to identify priority areas for pancreatic cancer care, set performance targets and reduce variations in care across England.



During the GIRFT national speciality review of pancreatic cancer services, NPaCA findings were used by the GIRFT team to highlight both inter- and intra-network variation, supporting constructive discussions with clinical teams about access to disease-targeted treatment and pathway performance.

"We are proud of our strong partnership with NPaCA. NPaCA has delivered sorely needed disaggregated data about pancreatic cancer treatment and care. This has enabled us to better understand the true picture of the variation data in pancreatic cancer care in England and Wales and has provided the granular evidence we need to support individual providers to improve their services."

Johanna Taylor
Policy and Health Improvement Manager,
Pancreatic Cancer UK



"NPaCA data has been invaluable in identifying variations in diagnostic pathways, non-surgical oncology provision and chemotherapy delivery resources that were otherwise unseen, which has enabled us to provide recommendations and support to pancreatic networks to address these."

Professor Daniel Palmer
Joint GIRFT Clinical lead for pancreatic
Cancer

